Eribulin monotherapy in heavily pretreated metastatic breast cancer patients in real life

dc.contributor.author	Sari, Murat
dc.contributor.author	Saip, Pinar
dc.date.accessioned	2021-03-05T13:37:33Z
dc.date.available	2021-03-05T13:37:33Z
dc.date.issued	2020
dc.identifier.citation	Sari M., Saip P., "Eribulin monotherapy in heavily pretreated metastatic breast cancer patients in real life", INDIAN JOURNAL OF CANCER, cilt.57, ss.55-61, 2020
dc.identifier.issn	0019-509X
dc.identifier.other	av_b313f349-469b-4723-9aee-8a12160438b7
dc.identifier.other	vv_1032021
dc.identifier.uri	http://hdl.handle.net/20.500.12627/119298
dc.identifier.uri	https://doi.org/10.4103/ijc.ijc_458_18
dc.description.abstract	Background and Aim: Our retrospective, single-center study aimed at evaluating the efficacy and safety of eribulin in heavily pretreated metastatic breast cancer (MBC) in routine clinical practice.
dc.language.iso	eng
dc.subject	Sağlık Bilimleri
dc.subject	Onkoloji
dc.subject	Dahili Tıp Bilimleri
dc.subject	İç Hastalıkları
dc.subject	Tıp
dc.subject	Klinik Tıp (MED)
dc.subject	Klinik Tıp
dc.subject	ONKOLOJİ
dc.title	Eribulin monotherapy in heavily pretreated metastatic breast cancer patients in real life
dc.type	Makale
dc.relation.journal	INDIAN JOURNAL OF CANCER
dc.contributor.department	İstanbul Teknik Üniversitesi , ,
dc.identifier.volume	57
dc.identifier.issue	1
dc.identifier.startpage	55
dc.identifier.endpage	61
dc.contributor.firstauthorID	2275921

Bu öğenin dosyaları:

Dosyalar	Boyut	Biçim	Göster
Bu öğe ile ilişkili dosya yok.